2013
DOI: 10.1159/000349942
|View full text |Cite
|
Sign up to set email alerts
|

New Generation Synthetic Surfactants

Abstract: The treatment of preterm newborn rabbits with synthetic surfactants containing simple phospholipid mixtures and peptides gives similar tidal volumes to treatment with poractant alfa (Curosurf®). The addition of both surfactant protein B and C analogs to the phospholipid mixture will stabilize the alveoli, measured as lung gas volumes at end expiration, even if no positive end-expiratory pressure is applied. The effect on lung gas volumes seems to depend on the structure of the peptides as well as the phospholi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
27
0
2

Year Published

2014
2014
2024
2024

Publication Types

Select...
7
2

Relationship

2
7

Authors

Journals

citations
Cited by 40 publications
(29 citation statements)
references
References 34 publications
0
27
0
2
Order By: Relevance
“…Development of clinically active synthetic surfactants has turned out to be very difficult since highly active natural surfactant preparations have a very complex composition with at least 50 different phospholipids (PL) and specific hydrophobic surfactant proteins which are either structurally complex and/or unstable in pure form [1,2]. …”
Section: Introductionmentioning
confidence: 99%
“…Development of clinically active synthetic surfactants has turned out to be very difficult since highly active natural surfactant preparations have a very complex composition with at least 50 different phospholipids (PL) and specific hydrophobic surfactant proteins which are either structurally complex and/or unstable in pure form [1,2]. …”
Section: Introductionmentioning
confidence: 99%
“…Apart from a reduction in neonatal mortality and pulmonary air leaks, surfactant therapy has had a significant effect in lowering overall infant mortality in the developed world. Future developments in the treatment of neonatal respiratory disorders include the production of new-generation synthetic surfactant preparations [78] and a better understanding of the genetic causes of acute and chronic neonatal lung diseases - termed ‘the molecular era of surfactant biology' by Whitsett [79]. …”
Section: Resultsmentioning
confidence: 99%
“…In October 2012, a first study in humans (phase I) was initiated to evaluate the intratracheal administration of CHF5633 [78]. A total of 12 investigational sites were involved in this multicenter, open-label trial - 4 in Germany, 6 in the UK and 2 in the Czech Republic.…”
Section: New-generation Synthetic Surfactantmentioning
confidence: 99%
“…These surfactants differ in their composition and concentration of phospholipids and SP since they are lipid extractions that only contain SP-B and SP-C. From the beginning in surfactant research, attempts were made to develop a synthetic surfactant. Synthetic surfactant may have more consistent and predictable concentrations of the different components and may reduce the risk of animal-to-human infection, but have taken several steps in development to mimic the complexity of natural surfactants [4]. CHF 5633 is such a new third-generation synthetic surfactant containing 0.2% SP-B analog and 1.5% SP-C analog mixed with a DPPC:palmitoyloleoylphosphatidylglycerol ratio of 1:1 that has been tested in humans (NCT01651637; NCT02452476).…”
Section: Introductionmentioning
confidence: 99%